Roles
- Associate Professor of Clinical Medicine
-
Biography
Dr. Natori was born in Japan and earned his medical degree from Nagoya University School of Medicine. He completed his residency and infectious disease fellowship at St. Luke's International Hospital in Tokyo, Japan. Additionally, he finished his Transplant Infectious Disease fellowship at University Health Network, University of Toronto. Currently, Dr. Natori serves as a faculty member in the Division of Infectious Diseases at the Department of Clinical Medicine in the University of Miami Miller School of Medicine. He also holds the position of medical director of Solid Organ Transplant Infectious Diseases at the Miami Transplant Institute, Jackson Health System. -
Education & Training
Education
Licensures and Certifications
-
Honors & Awards
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Clinical Trials
Viewing 0 of 3 clinical trials.
-
This is a phase II study, randomized, double-blind, placebo-controlled, multi-center clinical trial in CMV seronegativeprospective liver transplant recipients to determine the efficacy of two doses of CMV-MVA Triplex vaccine pretransplant.
- Principal Investigator: Yoichiro Natori
- Study Phase: Phase II
- Enrollment Status: Open
-
Single center, prospective, interventional study to assess the efficacy of CMV T-cell immunity to predict CMV infection in CMV seropositive lung transplant recipients followed by immunological-guided prophylaxis. We will monitor cell-mediated immunity (CMI) in months 0(at the time of enrollment) 3, 4, 5, 6, 9 and 12. If CMV CMI becomes positive at 3, 4, or 5 months, prophylaxis will be stopped at that time. CMV prophylaxis will be discontinued at month 6 regardless of CMV CMI.
- Principal Investigator: Yoichiro Natori
- Study Phase: TBD
- Enrollment Status: Open
-
This is a 7-year, randomized, open-label, multi-center clinical trial to determine the relative efficacy of 100 days of PET vs 200 days of AP using EITHER VGCV or Letermovir for prevention of CMV disease by 1-year post-transplant and indirect outcomes of CMV infection by last follow-up in CMV D+R- kidney transplant recipients. Each arm (PET, AP) will include 180 patients for a total sample size of N=360. This sample size was chosen to detect a statistically significant different rate of CMV disease in CMV D+R- kidney transplants with PET (9%) vs AP (20%) with 80% power (2-sided test) and includes an allowance for 10% attrition. CMV D+R- KTRs will be enrolled within 7 days of transplant and randomized 1:1 to either the PET or AP arm. Randomization will be stratified by site and use of lymphocyte-depleting induction immunosuppression. Follow-up for key clinical outcomes (patient and graft survival, biopsy-proven acute allograft rejection, estimated GFR) will occur until death, withdrawal, or end of study.
- Principal Investigator: Yoichiro Natori
- Study Phase: TBD
- Enrollment Status: Open